NCT00550732View on ClinicalTrials.gov

A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractory Fungal Infections (P05090 AM2)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Mycoses

Interventions

DRUG

Posaconazole

Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.